Seeking Alpha

Goldman Sachs starts coverage on Regeneron Pharma (REGN +0.7%) with a Buy and $144 price target,...

Goldman Sachs starts coverage on Regeneron Pharma (REGN +0.7%) with a Buy and $144 price target, propelled by its Eylea drug for various eye diseases that lead to vision loss. The firm anticipates "continued robust uptake of Eylea (GS WW peak sales of $4B, $2.3B in U.S.), which we project will propel the company to sustainable profitability in 4Q12."
Comments (1)
  • spald_fr
    , contributor
    Comments (2702) | Send Message
     
    This is terrific news, as Goldman Sachs can provide all manner of females for the clinical trials: http://reut.rs/H7gMWM
    2 Apr 2012, 10:53 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|